Skip to main content
EXELIXIS, INC. logo

EXELIXIS, INC. — Investor Relations & Filings

Ticker · EXEL ISIN · US30161Q1040 LEI · 254900PJQB59O2O95R37 US Manufacturing
Filings indexed 1,549 across all filing types
Latest filing 2026-03-26 Major Shareholding Noti…
Country US United States of America
Listing US EXEL

About EXELIXIS, INC.

https://www.exelixis.com/

Exelixis, Inc. is an oncology-focused biotechnology company that discovers, develops, and commercializes therapies for cancer treatment. The company's primary commercial product is cabozantinib, a small molecule inhibitor marketed for multiple cancer indications, including neuroendocrine tumors and certain types of carcinoma. Leveraging a genomics-based approach, Exelixis advances a diverse pipeline of potential medicines. Its research and development programs encompass in-house small molecule discovery and an expanding portfolio of biotherapeutics, such as antibody-drug conjugates and bispecific antibodies. The company pursues both next-generation approaches to established targets and first-in-class opportunities to address unmet needs in oncology.

Recent filings

Filing Released Lang Actions
SCHEDULE 13G/A - EXELIXIS, INC. (0000939767) (Subject)
Major Shareholding Notification
2026-03-26 English
4 - EXELIXIS, INC. (0000939767) (Filer)
Director's Dealing
2026-03-03 English
4 - EXELIXIS, INC. (0000939767) (Filer)
Director's Dealing
2026-03-03 English
4 - EXELIXIS, INC. (0000939767) (Filer)
Director's Dealing
2026-03-03 English
4 - EXELIXIS, INC. (0000939767) (Filer)
Director's Dealing
2026-03-03 English
4 - EXELIXIS, INC. (0000939767) (Filer)
Director's Dealing
2026-03-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.